Rheumatoid Arthritis. Seropositive rheumatoid arthritis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Age between 18 to 65 years Score 6 out of ten ACR / EULAR 2010 criteriaModerate-severe disease according to SDAI criteria (above 11) Patients who continue to have joint pain and swelling despite receiving standard medications (methotrexate, hydroxychloroquine, sulfasalazine, and prednisolone). The type of drug and its dose should be constant for at least 1 month before the study and remain the same during the study. Filling in the written consent
Exclusion criteria
Exclusion criteria: pregnancy and lactation diabetes melitus HF with EF<40% severe infection need IV antibiotics smoking more than 10 cigarette per day
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Laboratory response. Timepoint: At the beginning of the study and 3 months later. Method of measurement: based on simplified disease activity index (SDAI).;Clinical response to treatment (improved function of joints and morning dryness). Timepoint: At the beginning of the study and 3 months later. Method of measurement: Based on patient interview and clinical examination.;Serum level of ESR, CRP, IL-1, TNF-a. Timepoint: At the beginning of the study and 3 months later. Method of measurement: laboratory exam. | — |
Secondary
| Measure | Time frame |
|---|---|
| Finally the patient is clinically. Timepoint: End of treatment. Method of measurement: Clinical examination and laboratory results. | — |
Countries
Iran (Islamic Republic of)
Contacts
Gonabad University of Medical Sciences